Sedgefield, UK. 6 March 2012. Reinnervate, the leading expert in 3D cell culture, will be exhibiting and presenting at the upcoming 3D Cell Culture 2012 meeting being held in Zurich (14 to 16 March). As part of the stream ‘Enabling Technologies - Devices for 3D Cell Culture’, Reinnervate’s Chief Scientific Officer, Professor Stefan Przyborski, will deliver a presentation entitled “Optimal growth of cells in 3D culture relies on the appropriate shape and form of the supporting scaffold”, which takes place on Wednesday 14 March at 16.40.
Reinnervate will also exhibit at the meeting (stand number 15), where the company’s experts will be on hand to discuss the benefits of 3D cell culture, as well as the strengths of Reinnervate’s award-winning 3D growth scaffold, Alvetex®. This innovative product helps researchers to gain more relevant biological insight from their experiments than that offered by 2D models, by allowing cultures to grow in a way that more closely mimics the normal formation of tissues in the body.
For more information about 3D cell culture, Alvetex and Reinnervate, please visit www.reinnervate.com.
Alvetex® is a unique polystyrene material that provides a robust and inert scaffold for cells to grow and form complex 3D structures in the laboratory, mimicking the normal growth and formation of tissues in the body. Reinnervate has extensively tested and validated Alvetex with a large number of cell types, including liver, skin, cancer and stem cells, all of which have important applications in basic research into cell development, disease modelling and drug safety screening.
Alvetex has been launched globally in several formats: a 12-well culture plate, 6-well and 12-well inserts and a deep petri dish. These formats provide researchers with an exceptional degree of versatility in how they choose to construct different 3D cell culture models. Through enabling alternative applications, such as long-term 3D cell culture over several weeks, 3D cell growth at air/liquid interface and 3D cell growth with different media constituents, to be performed simply and routinely, Reinnervate continues to make genuine 3D cell culture a reality for researchers today.
Alvetex was named among the winners of The Scientist magazine’s “Top 10 Life Science Innovations of 2010” and was selected among the most technologically significant of 2010 in the 49th Annual R&D100 Awards.
See the company video - www.reinnervate.com/company-video
For further information, please contact
Ashley Cooper, Chief Executive Officer
+44 (0)1740 625266
+44 (0) 1489 557672
Reinnervate is an innovative life sciences company dedicated to making routine 3D cell culture a reality for researchers in academia and in the pharmaceutical and related industries.
Reinnervate’s core technology is Alvetex®, a unique and proprietary scaffold that enables routine 3D cell culture in the laboratory. Alvetex provides a nanoscale environment that supports genuine homogeneous 3D cell growth. Cells grown using Alvetex form complex 3D tissue cultures which more closely mimic normal in-vivo cell growth and the formation of tissues in the body than conventional techniques. The use of Alvetex-derived 3D cell cultures can provide researchers with greater insight into how cells behave in the body in response to external factors (such as drug candidates) than is currently possible with existing 2D or other emerging 3D cell culture technologies.
Reinnervate has generated significant data, which have been published extensively in peer-reviewed publications, exemplifying the use of Alvetex in a large number of cell types and applications. Alvetex has been launched globally in several formats: a 12-well culture plate, 6-well and 12-well inserts and a deep well petri dish.
Reinnervate continues to develop its technology for use in the 3D cell culture. During 2012 Reinnervate will deliver further innovative products to help researchers improve the growth and function of their cultured cells
Reinnervate was founded in 2002 based on the pioneering research of Professor Stefan Przyborski and his lab at Durham University, UK, and is funded by NorthStar Equity Investors (NSEI), management and private investors.